...
首页> 外文期刊>Die Pharmazie >Controlled release of nifedipine from mucoadhesive tablets of its inclusion complexes with beta-cyclodextrin.
【24h】

Controlled release of nifedipine from mucoadhesive tablets of its inclusion complexes with beta-cyclodextrin.

机译:硝苯地平与β-环糊精的包合复合物从粘膜粘附片中受控释放。

获取原文
获取原文并翻译 | 示例
           

摘要

Mucoadhesive tablets formulated with nifedipine (N) alone and its inclusion complexes with beta-cyclodextrin (betaCD) and the mucoadhesive polymers sodium carboxy methylcellulose and carbopol were investigated with a view to the design of oral controlled release tablets of nifedipine. As nifedipine is practically insoluble in water and aqueous fluids, its complexation with betaCD was investigated to improve its solubility and dissolution rate. Complexation of nifedipine with betaCD has markedly enhanced the solubility and dissolution rate of nifedipine. The phase solubility studies indicated the formation of a N-betaCD inclusion complex with a stability constant of 121.9 M(-1). A 20.6 fold increase in the dissolution rate of nifedipine was observed with N-betaCD (1:2) solid inclusion complex. Mucoadhesive tablets formulated employing nifedipine alone gave very low dissolution, whereas those formulated employing its betaCD inclusion complexes gave slow, controlled and complete release spread over a period of 12 h. Drug release from these tablets followed zero order kinetics up to 85-90% release and the release was diffusion controlled. Good controlled release two layered tablet formulations of nifedipine, satisfying the theoretical sustained release requirements based on its pharmacokinetics, were developed using its inclusion complexes with betaCD.
机译:为了设计口服硝苯地平控释片,研究了仅用硝苯地平(N)及其与β-环糊精(βCD)的包合配合物和羧甲基纤维素钠和卡波姆的粘膜黏附剂配制的粘膜粘附剂片剂。由于硝苯地平实际上不溶于水和水性液体,因此研究了它与βCD的络合作用以提高其溶解度和溶解速度。硝苯地平与βCD的络合已显着提高了硝苯地平的溶解度和溶解速度。相溶解度研究表明形成了具有121.9 M(-1)稳定常数的N-betaCD包合物。使用N-βCD(1:2)固体包合物可以观察到硝苯地平的溶出度增加20.6倍。仅使用硝苯地平配制的粘膜粘着剂的溶出度非常低,而使用其βCD包合物形成的粘膜粘着剂在12小时内可缓慢,控制和完全释放。从这些片剂中释放的药物遵循零级动力学,直至高达85-90%的释放,并且该释放是受扩散控制的。硝苯地平具有良好的控释性两层片剂,其药代动力学可满足其基于药代动力学的理论缓释要求,并与βCD形成包合物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号